NCT05530330|Completed
Markers of Platelet Activation foR Identification of Late Onset Sepsis in Preterm Infants
PARENT
Loading search results
PARENT
Sponsor study identifier
observational
268
1 country
2
Study Start
September 2, 2022
Actual (reported)Primary Completion
February 28, 2025
Actual (reported)Study Completion
June 27, 2025
Actual (reported)The PARENT study will examine platelet and endothelial associated proteins in preterm infants being investigated for late onset sepsis (LOS) to see if infants with fulminant sepsis can be prospectively identified using these markers
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 27, 2025
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2, 2022
Actual (reported)September 2, 2022
Actual (reported)September 7, 2022
Actual (reported)February 28, 2025
Actual (reported)June 27, 2025
Actual (reported)A difference exists between infants with culture proven late onset sepsis and those without in platelet and endothelial proteomic profiles
Proteomic profiles including extracellular vesicles will be compared between those with and without culture proven sepsis
3 years
To examine platelet markers in this same cohort and determine if they can distinguish between culture negative sepsis and non-sepsis
3 years
To determine if platelet activation markers correlate with severity of illness as established by prospective use of validated clinical scoring systems ( the novel neonatal Sequential organ failure assessment)
3 years
To determine if platelet activation markers predict the development of necrotising enterocolitis (Radiological/Surgical)
3 years
Infants who are being investigated for late onset sepsis will be included. These infants may ultimately be classified in a number of ways, including culture positive late onset sepsis, culture negative late onset sepsis, necrotising enterocolitis or non infectious etiologies suspected (i.e prematurity)
Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Preterm infants less than 34 weeks corrected gestational age at birth who are undergoing investigations for late onset sepsis
The National Maternity Hospital
Dublin, Dublin, D2, Ireland
The Rotunda Hospital
Dublin, Ireland
O'Reilly D, Murphy CA, Moore CM, Ni Ainle F, Gormley IC, Morrell CN, Curley A, Mc Callion N, Maguire P. Markers of platelet activation foR identification of late onset sEpsis in infaNTs: PARENT study protocol. Pediatr Res. 2024 Feb;95(3):852-856. doi: 10.1038/s41390-023-02812-x. Epub 2023 Sep 27.
0.5-1.3ml sodium citrate sample taken depending on infant weight
Patricia Maguire
University College Dublin
268 participants (actual enrollment reported by the registry).
First Submitted
September 2, 2022
First Posted
September 7, 2022
Study Start
September 2, 2022
Actual (reported)Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.
Contact the study team to confirm eligibility.
Primary Completion
February 28, 2025
Actual (reported)Study Completion
June 27, 2025
Actual (reported)Last Updated
July 3, 2025
Record last verified: 2024-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: